Background and Purpose-People with end-stage kidney disease (ESKD) are at greater risk of stroke. We aimed to compare stroke mortality between the ESKD population and the general population. Methods-We included all patients with incident ESKD in Australia, 1980, and New Zealand, 1988 to 2012. The primary cause of death was ascertained using data linkage with national death registers. We produced standardized mortality ratios for stroke deaths, by age, sex, and calendar year. Results-We included 60 823 patients with ESKD, where 941 stroke deaths occurred during 381 874 person-years. Patients with ESKD had >3× the stroke deaths compared with the general population (standardized mortality ratio, 3.4; 95% CI, 3.2-3.6), markedly higher in younger people and women. The greatest excess was in intracerebral hemorrhages (standardized mortality ratio, 5.2; 95% CI, 4.5-5.9). Excess stroke deaths in patients with ESKD decreased over time, although were still double in 2013 (2013 standardized mortality ratio, 2.1; 95% CI, 1.5-2.9). Conclusions-People with ESKD experience much greater stroke mortality with the greatest difference for women and younger people. However, mortality has improved over time.
P eople with end-stage kidney disease (ESKD) are at greater risk of stroke, with stroke hospitalizations 2 to 3× that of the general population. 1 Despite the increased risk of stroke, how ESKD affects stroke mortality remains unclear. Limited trial data suggest some interventions are less effective in patients with ESKD, where statin therapy and warfarin have little-to-no effect on reducing stroke events. 2, 3 We aimed to compare stroke mortality rates for the ESKD population versus the general population, using a population-based approach.
Methods
Study data are available to qualified researchers from the corresponding author, subject to study and ethical approvals.
Participants, Data Linkage, and Death Outcomes
We used prospective observational data collected in the Australian and New Zealand Dialysis and Transplant Registry, which includes all people with ESKD from initiation of ESKD treatment. Nationwide summary-level data were used to determine stroke mortality rates in the general population in Australia and in New Zealand. Both countries provided the number of deaths by underlying cause of death using International Classification of Diseases 10th revision Australian Modification, sex, 5-year age band, and calendar year.
We used data linkage of Australian and New Zealand Dialysis and Transplant Registry to the national death registers to ascertain date and cause of death. We linked Australian patients with ESKD using probabilistic record linkage and New Zealand patients with ESKD using deterministic record linkage. Because of limited data in the national death registers, we only included patients with incident ESKD in Australia, 1980 to 2013, and in New Zealand, 1988 to 2012.
Stroke deaths were determined from the underlying cause of death only using International Classification of Diseases 10th revision Australian Modification codes. All other causes of death were considered as nonstroke deaths.
Statistical Analyses
Patient follow-up was from ESKD treatment initiation date until the earliest date of; death, 31 December 2013 (Australia) or 31 December 2012 (New Zealand). We produced mortality rates and standardized mortality ratios (SMR). The overall cumulative incidence of stroke mortality was estimated by summing to time t the Kaplan-Meier estimate of the overall survival function, S(t−1), multiplied by the causespecific hazard at time t.
Ethical approval was granted from the University of Sydney 
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Results

Patient Characteristics
We included 60 823 patients with incident ESKD, where death agreement between Australian and New Zealand Dialysis and Transplant Registry and the national death registry was almost perfect (κ-statistic, 0.85; Table I in the online-only Data Supplement). There were 26 505 (41%) patients still alive, and 34 318 (59%) patients had died ( Figure I in the onlineonly Data Supplement). There were 941 stroke deaths during 381 874 person-years of follow-up, with median follow-up of 4 years (Table II in the online-only Data Supplement).
Deaths
Of the 941 stroke deaths, there were 259 (27%) intracerebral hemorrhages, 90 (10%) intracranial hemorrhages, 108 (12%) ischemic strokes, 68 (7%) subarachnoid hemorrhages, 302 (32%) unspecified strokes, and 114 (12%) transient cerebral ischemic attacks and related syndromes. The cumulative incidence of all-cause stroke mortality was 1.4% (95% CI, 1.3%-1.6%) in women and 1.0% (95% CI, 0.9%-1.1%) in men at 5 years ( Figure 1 ).
Stroke Mortality Rates
Overall, the crude mortality rate for all-cause stroke was 246.4 (95% CI, 231.2-262.7) per 100 000 person-years. The all-cause stroke mortality rates showed a clear increasing trend with age for both sexes ( Figure II in the online-only Data Supplement). However, there was little evidence of a trend or sex difference for mortality rates in ischemic strokes and intracerebral hemorrhages ( Figure II in the online-only Data Supplement). The all-cause stroke mortality showed a slight decreasing trend in more recent years. The all-cause stroke mortality rate per 100 000 person-years decreased from 245.7 (95% CI, 132.2-456.7) in 1988 to 194.4 (95% CI, 146.1-258.8) in 2011. There was little evidence of a consistent pattern for stroke mortality rates over calendar year for ischemic strokes or intracerebral hemorrhages.
Stroke Mortality SMRs
The all-cause stroke SMR was 3.4 (95% CI, 3.2-3.6), ischemic stroke was 3.1 (95% CI, 2.6-3.7), and intracerebral hemorrhage was 5.2 (95% CI, 4.5-5.9). The all-cause stroke SMRs were greater in younger age and for women ( Figure 2A ; Table III in the online-only Data Supplement). These SMRs decreased with age, where stroke mortality rates in the ESKD population were comparable with the general population when aged >75 years. The SMRs for ischemic strokes and intracerebral hemorrhages followed a similar trend (Figure 2B and 2C ; Table III in the online-only Data Supplement).
The all-cause stroke SMR decreased over time ( Figure 3A ). The SMRs were the highest in 1988 to 1998, where the SMR reduced from 4.1(95% CI, 2.9-5.6) in 1998 to 2.1 (95% CI, 1.5-2.9) in 2013. Since 2000, the intracerebral hemorrhage SMRs have stabilized around 5 (2013: 5.2 SMR; 95% CI, 3.1-8.8; Figure 3B ). Ischemic stroke SMRs were substantially varied before 1998, after which SMRs were relatively stable at <5 (2013: 1.7 SMR; 95% CI, 0.7-4.6; Figure 3C ).
Discussion
Our work represents the largest cohort study to date examining stroke death in people with ESKD. During 30 years, in a dual-national comparison, people with ESKD had more than Standardized mortality ratios (SMRs) for people with end-stage kidney disease, stratified by age and sex, in (A) all-cause strokes, (B) intracerebral hemorrhages, and (C) ischemic strokes. P are test for trend across age groups. x marks in graph indicate the 95% CI has been cut.
3-fold increased risk of stroke death compared with age-and sex-matched people in the general population, predominantly from hemorrhagic stroke. The relative risk of stroke death was the highest for younger people and women. Although stroke death rates have decreased rapidly in people with ESKD, the risk of stroke death in 2013 was still double that of the general population.
We found stroke deaths were more likely in people with ESKD compared with the general population, being greater for intracerebral hemorrhage than ischemic stroke. Admission stroke severity and poststroke neurological deterioration increases progressively as estimated glomerular filtration rate decreases. 4 Preventative interventions may be ineffective in the ESKD population. Antithrombotic agents in people with ESKD are associated with increased bleeding and cardiovascular mortality, lacking evidence in reducing stroke incidence. 3, 5 Stroke thrombolysis in people with chronic kidney disease is associated with an increased risk of hemorrhagic transformation and mortality. 6 ESKD-specific factors may also increase bleeding risk, such as frequent anticoagulation with heparin (on hemodialysis) and uremia-induced impaired platelet function. One study found that 35% of hemorrhagic strokes occurred during or within 30 minutes after hemodialysis. 7 Dialysis patients are also less likely to be managed in an acute stroke unit and receive poststroke care compared with patients without chronic kidney disease. 8 Second, age and sex varied the risk of stroke death in people with ESKD. Younger people experienced ≤15× the stroke deaths than expected. This suggests the greatest potential benefit for stroke interventions is among the young. 9 The relative protective effect of being female seen in the general population for Australia and New Zealand, where women have 20% to 30% lower risk of stroke death, is lost in ESKD. Women with ESKD reach menopause 5 years earlier than people without ESKD and are frequently amenorrheic at ESKD diagnosis, losing the protective effect of estrogen earlier than expected. 10 Stroke prevention strategies may be implemented less often in women, and sex differences in the setting of poststroke care may exist. 11 Finally, excess stroke deaths in the ESKD population decreased over time, particularly in 1998 to 2003. An increased prevalence of kidney transplants, which are associated with reduced cardiovascular risk compared with dialysis, better transplant survival, and increased living kidney donation, may all contribute to this reduction in risk. 12 Changes over time in the risk factors for stroke death in the general population may have also contributed to the varied SMR over time, although from available data, shifts in risk factors do not seem to be different for the ESKD and general populations. A more granular analysis of standardized death rates and ratios by presence of risk factors is not possible because general population death data are not stratified by risk factors, such as smoking, hypertension, or diabetes mellitus, in either country, or indeed globally. Regardless, the overall prevalence of these risk factors in the general population has shown similar trends in both Australia and New Zealand. Smoking has decreased from 22.4% (2001) (2015) in New Zealand. The prevalence of hypertension and diabetes mellitus have remained stable since 2011 (hypertension: 11% in Australia and 16% in New Zealand; diabetes: 4% in Australia and 6% in New Zealand). 13, 14 In addition, the age distribution for these conditions has not varied over time. These trends have also been reflected in the ESKD population, where the prevalence of current smoking has decreased from 15% before 1990 to 12% in 2010 to 2013. 15 Diabetes mellitus causing ESKD has been stable at 45%. Hypertension is common as a cause or consequence of ESKD and has not changed over time.
There are several limitations to our study. The primary cause of death was ascertained from the national death register only, which does not capture overseas deaths, although typically people with ESKD are not internationally mobile. 
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Large CIs occurred when stratum-specific sample sizes or general population mortality rates were low, evident in younger age bands and <1997. We were limited to the patient treatment data recorded by Australian and New Zealand Dialysis and Transplant Registry, where the use of primary or secondary stroke prevention drugs is not recorded.
In conclusion, we found that all-cause stroke deaths were >3× higher in the ESKD population than expected. Further research is needed into stroke prevention, treatment, and care provided to patients with ESKD, particularly in women and younger ESKD patients. Future studies explicitly including people with ESKD are required to evaluate the effectiveness, tolerability, and safety of stroke prevention drugs and treatment. A better understanding of the current use of stroke prevention and care after stroke in the ESKD population would be useful to determine whether further improvements are possible.
